The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

B. V. Balgobind; C. M. Zwaan; R. Pieters; M. M. Van Den Heuvel-Eibrink

doi:10.1038/leu.2011.90

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

B. V. Balgobind, C. M. Zwaan, R. Pieters, M. M. Van Den Heuvel-Eibrink

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

107 Citaten (Scopus)

Samenvatting

Translocations involving the mixed-lineage leukemia (MLL) gene, localized at 11q23, comprise 15 to 20% of all pediatric acute myeloid leukemia (AML) cases. This review summarizes current knowledge about the etiology, biology, clinical characteristics and differences in outcome in MLL-rearranged pediatric AML. Furthermore, we discuss the role of cooperating events in MLL-rearranged pediatric AML, and future therapeutic strategies to improve outcome. We conclude that MLL-rearranged pediatric AML is a heterogeneous disease, and prognosis depends on various factors, for example, translocation partner, age, WBC and additional cytogenetic aberrations. The relationship of outcome with specific translocation partners requires that they be searched for in the diagnostic work-up of AML. To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted.

Originele taal-2	Engels
Pagina's (van-tot)	1239-1248
Aantal pagina's	10
Tijdschrift	Leukemia
Volume	25
Nummer van het tijdschrift	8
DOI's	https://doi.org/10.1038/leu.2011.90
Status	Gepubliceerd - aug. 2011
Extern gepubliceerd	Ja

Toegang tot document

10.1038/leu.2011.90

Citeer dit

@article{444490b01c494b1584949ee86cd70c99,

title = "The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia",

abstract = "Translocations involving the mixed-lineage leukemia (MLL) gene, localized at 11q23, comprise 15 to 20% of all pediatric acute myeloid leukemia (AML) cases. This review summarizes current knowledge about the etiology, biology, clinical characteristics and differences in outcome in MLL-rearranged pediatric AML. Furthermore, we discuss the role of cooperating events in MLL-rearranged pediatric AML, and future therapeutic strategies to improve outcome. We conclude that MLL-rearranged pediatric AML is a heterogeneous disease, and prognosis depends on various factors, for example, translocation partner, age, WBC and additional cytogenetic aberrations. The relationship of outcome with specific translocation partners requires that they be searched for in the diagnostic work-up of AML. To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted.",

keywords = "heterogeneity, MLL, pediatric AML",

author = "Balgobind, {B. V.} and Zwaan, {C. M.} and R. Pieters and {Van Den Heuvel-Eibrink}, {M. M.}",

year = "2011",

month = aug,

doi = "10.1038/leu.2011.90",

language = "English",

volume = "25",

pages = "1239--1248",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

AU - Balgobind, B. V.

AU - Zwaan, C. M.

AU - Pieters, R.

AU - Van Den Heuvel-Eibrink, M. M.

PY - 2011/8

Y1 - 2011/8

N2 - Translocations involving the mixed-lineage leukemia (MLL) gene, localized at 11q23, comprise 15 to 20% of all pediatric acute myeloid leukemia (AML) cases. This review summarizes current knowledge about the etiology, biology, clinical characteristics and differences in outcome in MLL-rearranged pediatric AML. Furthermore, we discuss the role of cooperating events in MLL-rearranged pediatric AML, and future therapeutic strategies to improve outcome. We conclude that MLL-rearranged pediatric AML is a heterogeneous disease, and prognosis depends on various factors, for example, translocation partner, age, WBC and additional cytogenetic aberrations. The relationship of outcome with specific translocation partners requires that they be searched for in the diagnostic work-up of AML. To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted.

AB - Translocations involving the mixed-lineage leukemia (MLL) gene, localized at 11q23, comprise 15 to 20% of all pediatric acute myeloid leukemia (AML) cases. This review summarizes current knowledge about the etiology, biology, clinical characteristics and differences in outcome in MLL-rearranged pediatric AML. Furthermore, we discuss the role of cooperating events in MLL-rearranged pediatric AML, and future therapeutic strategies to improve outcome. We conclude that MLL-rearranged pediatric AML is a heterogeneous disease, and prognosis depends on various factors, for example, translocation partner, age, WBC and additional cytogenetic aberrations. The relationship of outcome with specific translocation partners requires that they be searched for in the diagnostic work-up of AML. To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted.

KW - heterogeneity

KW - MLL

KW - pediatric AML

UR - http://www.scopus.com/inward/record.url?scp=80051790435&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.90

DO - 10.1038/leu.2011.90

M3 - Review article

C2 - 21566656

AN - SCOPUS:80051790435

SN - 0887-6924

VL - 25

SP - 1239

EP - 1248

JO - Leukemia

JF - Leukemia

IS - 8

ER -

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit